MMP11: A novel target antigen for cancer immunotherapy

Clinical Cancer Research

Volumn 15, Issue 12, 2009, Pages 4104-4113

  Peruzzi, Daniela ^a   Mori, Federica ^a   Conforti, Antonella ^a   Lazzaro, Domenico ^a   De Rinaldis, Emanuele ^a   Ciliberto, Gennaro ^a   La Monica, Nicola ^a   Aurisicchio, Luigi ^a,b  

^a Merck Research Laboratories   (Italy)

^b IRBM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPITOPE; HLA A2 ANTIGEN; HLA A2.1 ANTIGEN; HUMAN MATRIX METALLOPROTEINASE 327; MATRIX METALLOPROTEINASE; PLASMID DNA; STROMELYSIN 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER PREVENTION; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; EPITOPES; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; MATRIX METALLOPROTEINASE 11; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEOPLASMS; TRANSFECTION;

EID: 67449127081     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3226     Document Type: Article

References (41)

1. Wei L, Shi YB. Matrix metalloproteinase stromelysin-3 in development and pathogenesis. Histol Histopathol 2005;20:177-185 (Pubitemid 40028996)
2. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-174 (Pubitemid 37328786)
3. Mari BP, Anderson IC, Mari SE, et al. Stromelysin-3 is induced in tumor/stroma cocultures and inactivated via a tumor-specific and basic fibroblast growth factor-dependent mechanism. J Biol Chem 1998;273:618-626 (Pubitemid 28042253)
4. Arora S, Kaur J, Sharma C, et al. Stromelysin 3, Ets-1, and vascular endothelial growth factor expression in oral precancerous and cancerous lesions: correlation with microvessel density, progression, and prognosis. Clin Cancer Res 2005;11:2272-2284 (Pubitemid 40490187)
5. Yang YH, Deng H, Li WM, et al. Identification of matrix metalloproteinase 11 as a predictive tumor marker in serum based on gene expression profiling. Clin Cancer Res 2008;14:74-81.
6. Deng H, Guo RF, Li WM, Zhao M, Lu YY. Matrix metalloproteinase 11 depletion inhibits cell proliferation in gastric cancer cells. Biochem Biophys Res Commun 2005;326:274-281 (Pubitemid 39610456)
7. Vazquez-Ortiz G, Pina-Sanchez P, Vazquez K, et al. Overexpression of cathepsin F, matrix metalloproteinases 11 and 12 in cervical cancer. BMC Cancer 2005;5:68. (Pubitemid 41461063)
8. Basset P, Okada A, Chenard MP, et al. Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol 1997;15:535-541 (Pubitemid 27190028)
9. Noel AC, Lefebvre O, Maquoi E, et al. Stromelysin-3 expression promotes tumor take in nude mice. J Clin Invest 1996;97:1924-1930 (Pubitemid 26129880)
10. Masson R, Lefebvre O, Noel A, et al. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 1998;140:1535-1541
11. Noel A, Boulay A, Kebers F, et al. Demonstration in vivo that stromelysin-3 functions through its proteolytic activity. Oncogene 2000;19:1605-1612 (Pubitemid 30175683)
12. Boulay A, Masson R, Chenard MP, et al. High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res 2001;61:2189-2193 (Pubitemid 32692046)
13. Wu E, Mari BP, Wang F, Anderson IC, Sunday ME, Shipp MA. Stromelysin-3 suppresses tumor cell apoptosis in a murine model. J Cell Biochem 2001;82:549-555 (Pubitemid 32720670)
14. Andarawewa KL, Boulay A, Masson R, et al. Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. Cancer Res 2003;63:5844-5849 (Pubitemid 37187483)
15. Jia L, Wang S, Cao J, Zhou H, Wei W, Zhang J. siRNA targeted against matrix metalloproteinase 11 inhibits the metastatic capability of murine hepatocarcinoma cell Hca-F to lymph nodes. Int J Biochem Cell Biol 2007;39:2049-2062 (Pubitemid 47369239)
16. Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP, Boyd MT. Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 2004;10:2832-2845 (Pubitemid 38509163)
17. Thewes M, Pohlmann G, Atkinson M, Mueller J, Putz B, Hofler H. Stromelysin-3 (ST-3) mRNA expression in colorectal carcinomas. Localization and clinicopathologic correlations. Diagn Mol Pathol 1996;5:284-290
18. Choudhary G, Hansen H. Human health perspective on environmental exposure to hydrazines: a review. Chemosphere 1998;37:801-843 (Pubitemid 28362492)
19. Blakey DH, Duncan AM, Wargovich MJ, Goldberg MT, Bruce WR, Heddle JA. Detection of nuclear anomalies in the colonic epithelium of the mouse. Cancer Res 1985;45:242-249 (Pubitemid 15196962)
20. Ma QY, Williamson KE, Rowlands BJ. Variability of cell proliferation in the proximal and distal colon of normal rats and rats with dimethylhydrazine induced carcinogenesis. World J Gastroenterol 2002;8:847-852
21. Koesters R, Hans M, Benner A, Al E. Predominant mutation of codon 41 of the h-catenin proto-oncogene in rat colon tumors induced by 1,2- dimethylhydrazine using a complete carcinogenic protocol. Carcinogenesis 2001;22:1885-1890 (Pubitemid 33064856)
22. Hughes TR, Mao M, Jones AR, et al. Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat Biotechnol 2001;19:342-347 (Pubitemid 32275343)
23. Weng L, Dai H, Zhan Y, He Y, Stepaniants SB, Bassett DE. Rosetta error model for gene expression analysis. Bioinformatics 2006;22:1111-1121
24. Facciabene A, Aurisicchio L, Elia L, et al. Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects. Vaccine 2007;26:47-58. (Pubitemid 350213209)
25. Rizzuto G, Cap pelletti M, Maione D, et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci US A1999;96:6417-6422
26. Facciabene A, Aurisicchio L, La Monica N. Baculovirus vectors elicit antigen-specific immune responses inmice. J Virol 2004;78:8663-8672 (Pubitemid 39025132)
27. Mennuni C, Calvaruso F, Facciabene A, et al. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer 2005;117:444-455 (Pubitemid 41429568)
28. Giannetti P, Facciabene A, La Monica N, Aurisicchio L. Individual mouse analysis of the cellular immune response to tumor antigens in peripheral blood by intracellular staining for cytokines. J Immunol Methods 2006;316:84-96. (Pubitemid 44592593)
29. Rizzuto G, Cappelletti M, Mennuni C, et al. Gene electrotransfer results in a high-level transduction of rat skeletal muscle and corrects anemia of renal failure. Hum Gene Ther 2000;11:1891-1900 (Pubitemid 30676761)
30. Corpet DE, Pierre F. Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003;12:391-400.
31. Hata K, Yamada Y, Kuno T, et al. Tumor formation is correlated with expression of beta-catenin-accumulated crypts in azoxymethane-induced colon carcinogenesis in mice. Cancer Sci 2004;95:316-320 (Pubitemid 38519471)
32. Mori F, Piro FR, Della Rocca C, et al. Survivin and cyclooxygenase-2 are co-expressed in human and mouse colon carcinoma and in terminally differentiated colonocytes. Histol Histopathol 2007;22:61-77. (Pubitemid 46126650)
33. Iero M, Squarcina P, Romero P, et al. Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide. Cancer Immunol Immunother 2007;56:1979-1991 (Pubitemid 47512618)
34. Casimiro DR, Tang A, Perry HC, et al. Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized human immunodeficiency virus type 1 pol gene. J Virol 2002;76:185-194 (Pubitemid 33139004)
35. Aurisicchio L, Mennuni C, Giannetti P, et al. Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates. Int J Cancer 2007;120:2290-2300 (Pubitemid 46642113)
36. Mori F, Giannetti P, Peruzzi D, et al. A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas. Hum Gene Ther 2009;20:125-136
37. Kohno H, Suzuki R, Sugie S, Tanaka T. Beta-catenin mutations in a mouse model of inflammation-related colon carcinogenesis induced by 1,2-dimethylhydrazine and dextran sodium sulfate. Cancer Sci 2005;96:69-76. (Pubitemid 40425381)
38. Zhang B. Targeting the stroma by T cells to limit tumor growth. Cancer Res 2008;68:9570-9573
39. Hofmeister V, Schrama D, Becker JC. Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother 2008;57:1-17. (Pubitemid 350043655)
40. Yi T, Wei YQ, Tian L, et al. Humoral and cellular immunity induced by tumor cell vaccine based on the chicken xenogeneic homologous matrix metalloproteinase-2. Cancer Gene Ther 2007;14:158-164 (Pubitemid 46106960)
41. Yokoyama Y, Grunebach F, Schmidt SM, et al. Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells. Clin Cancer Res 2008;14:5503-5511